MEDICINAL CHEMISTRY BIOLOGY

STRATEGY MEETING EUROPE

29th JUNE 2020

Radisson BLU STANSTED

OUR UNIQUE MEETING FORMAT

- **Roundtable Discussions**
  These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants to share ideas, challenges and lessons learned.

- **Personalised Agenda**
  Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time out of the office is focused and well-utilised.

- **One-to-one Meetings**
  The most effective and time efficient way to assess potential partners at a strategic level. Gain access to our exclusive networking app to identify the people that you need to meet. The app suggests a suitable time and place, all you need to do is grab the coffee.

- **Strategic Networking**
  Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances is underscored by a host of networking programmes, from a buffet breakfast through to evening drinks, make lasting connections that benefit you.

CONTRIBUTORS TO THE AGENDA

Vincent Lawton
Chairman
Addex Therapeutics

Guy Lewy
CSO
Sublime Therapeutics

Alexander Scheer
CSO
Erytech Pharma

Paul Peter Tak
MD PhD President & CEO
Kintai Therapeutics

PJ Moloney
CEO
P4ML

Alun McCarthy
Vice President
C4X Discovery Ltd.

Garry Pairaudeau
Head of Hit Discovery
AstraZeneca

Asif Ahmed
Founder
MirZyme Therapeutics

Jascha Blobel
CEO
Molomics

Danilo Maddalo
Head of Medicinal Chemistry
Novartis

PROVENTA INTERNATIONAL

http://

MEDICINAL CHEMISTRY

AGENDA AT A GLANCE

TRACK & ROOM	01 AI & MACHINE LEARNING	02 DESIGN & CUSTOM SYNTHESIS	03 INTEGRATED DRUG DISCOVERY	04 HIT TO LEAD IDENTIFICATION	05 CHEMICAL BIOLOGY & CHEMINFORMATICS	06 DISRUPTIVE TECHNOLOGIES
08:00 - 08:30	REGISTRATION & BREAKFAST NETWORKING			REGISTRATION & BREAKFAST NETWORKING		
08:30 - 09:00	WELCOME SPEECH & INVESTOR'S PANEL DISCUSSION					
09:00 - 10:00	Advances in drug discovery using AI Tim Springer - CEO Novintum Bioscience	Generative algorithms & active learning approaches : enabling a more automated data-driven approach to the design cycle Gokhan Yahioglu - Director MedChem Biopharma Ltd.	Activation of endogenous progenitor cells by small molecules, leading to controlled tissue repair and regeneration Mauro Marigo - Head Medicinal Chem. Endogena	How will AI enhance Drug Design : Challenges and opportunities Garry Pairaudeau - Head of Hit Discovery AstraZeneca	Cheminformatics Tools for Analysing & Designing Optimized Small-Molecule Collections and Libraries Gerhard Hessler - Head CSSD Sanofi	High-Throughput Screening vs Fragment Based Drug Discovery PJ Moloney - CEO P4ML
10:00 - 11:00	1 - 1 MEETING *10:00-10:20	NETWORKING BREAK	1 - 1 MEETING *10:20-10:40	NETWORKING BREAK	1 - 1 MEETING *10:40-11:00	
11:00 - 12:00	PerkinElmer For the Better	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR	ROUND TABLE TOPIC CONFIRMED FOR SPONSOR	optibrium	CDD VAULT
12:00 - 13:00	1 - 1 MEETING *12:00-12:20		1 - 1 MEETING *12:20-12:40		1 - 1 MEETING *12:40-13:00	
13:00 - 14:00	1 - 1 MEETING *13:00-13:20	3 COURSE NETWORKING LUNCH	1 - 1 MEETING *13:20-13:40	3 COURSE NETWORKING LUNCH	1 - 1 MEETING *13:40-14:00	3 COURSE NETWORKING LUNCH
14:00 - 14:30	KEYNOTE PRESENTATION		KEYNOTE PRESENTATION		KEYNOTE PRESENTATION	
14:30 - 15:30	Practical Advice on the Implementation of AI/ML in Drug Discovery Graham Simpson - Head Therap. GSK	Optimizing Chemical Reactions with Deep Reinforcement Learning Mike Xelare - SVP MSD Int. GmbH	Speeding the drug discovery process: collaborations, partnerships and Open Access Janos Eles - Head MedChem Gedeon Richter	Hit and Lead Generation: Selection of screening sets and strategies to maximise success rates Andy Merritt - Head of Chemistry LifeArc Centre	Molecular adventures in 3D and 4D: What new ground is being opened up by cloud computing? Guy Lewy - CSO Sublime	How an integrated technology suite of solutions can improve compound library acquisition and design
15:30 - 15:40	AFTERNOON COFFEE BREAK			AFTERNOON COFFEE BREAK		
15:40 - 16:00	1 - 1 MEETING *20min		1 - 1 MEETING *20min		1 - 1 MEETING *20min	
16:00 - 17:00	How the use of A.I in Drug Discovery can decrease failure rates in clinical trials Jonathan Hay - Partner Delin Ventures	Making the molecule design cycle a success Jascha Blobel - CEO Molomics	Accelerating translation through strategic alliances Martin Swarbrick - Assoc. Director Cancer Research Uk Therap.	Providing unique chemical tools to probe kinetoplastid biology and as hit-to-lead candidates for drug discovery Tero Linnanen - Head Drug Disc. Fored Pharma	Connecting environmental exposure and neurodegeneration using cheminformatics: potential and challenges	How innovative techonologies can eliminate transcription errors through automatic data transfer between the SDMS and the ELN to help improve better decision making?
17:00 - 17:30	INVESTOR'S PANEL		INVESTOR'S PANEL		INVESTOR'S PANEL	
17:30 - 19:00	DRINKS & CANAPE RECEPTION		DRINKS & CANAPE RECEPTION		DRINKS & CANAPE RECEPTION	

PREVIOUS PAGE | GO TO MENU | NEXT PAGE

PROVENTA INTERNATIONAL

BIOLOGY

AGENDA AT A GLANCE

TRACK & ROOM	07 OUTSOURCING FOR EMERGING BIOPHARMA	08 DMPK & ADME	09 IN VIVO & IN VITRO PHARMACOLOGY	10 IND- PROOF OF CONCEPT	11 STRATEGIC PARTNERSHIP & OUTSOURCING	12 TARGET VALIDATION
08:00 - 08:30	REGISTRATION & BREAKFAST NETWORKING			REGISTRATION & BREAKFAST NETWORKING		
08:30 - 09:00	WELCOME SPEECH & INVESTOR'S PANEL DISCUSSION					
09:00 - 10:00	How a shared-risked partnership model can improve the success rates of getting to IND? **Asif Ahmed - Founder MirZyme Therapeutics**	The use of AI for decision making in drug discovery : How can applying AI in DMPK could impact in drug discovery? **Lassina Badolo - Director Disc. DMPK Merck**	Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug Discovery **Danilo Maddalo - Head MedChem Novartis**	Rethinking drug design in the artificial intelligence era **Maria Flocco - Vice President AstraZeneca**	Enabling business goals via collaborative or commercial alliances, both moderates risk and garners reward **Marc Ramis - CEO Senolytic Therapeutics**	What is a validated target? Discussion on generating new targets for drug discovery **Rob Howes - Director Disc. Biology AstraZeneca**
10:00 - 11:00	1 - 1 MEETING *10:00-10:20	NETWORKING BREAK	1 - 1 MEETING *10:20-10:40	NETWORKING BREAK	1 - 1 MEETING *10:40-11:00	
11:00 - 12:00	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR	ROUND TABLE TOPIC CONFIRMED FOR SPONSOR	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR	ROUND TABLE TOPIC CONFIRMED FOR SPONSOR
12:00 - 13:00	1 - 1 MEETING *12:00-12:20		1 - 1 MEETING *12:20-12:40		1 - 1 MEETING *12:40-13:00	
13:00 - 14:00	1 - 1 MEETING *13:00-13:20	3 COURSE NETWORKING LUNCH	1 - 1 MEETING *13:20-13:40	3 COURSE NETWORKING LUNCH	1 - 1 MEETING *13:40-14:00	3 COURSE NETWORKING LUNCH
14:00 - 14:30	KEYNOTE PRESENTATION		KEYNOTE PRESENTATION		KEYNOTE PRESENTATION	
14:30 - 15:30	The Effect of Brexit on the Emerging Biopharm sector in the UK. **Vincent Lawton - Chairman Addex Therapeutics**	MetID and metabolite profiling	in vitro and in silico Approaches to Study Cytochrome P450-Mediated Interactions. **Isabel Najera - CSO Virion Therapeutics**	Biophysics in drug discovery: impact, challenges and opportunities	Which are the criteria of establishing successful partnership and commercial alliances? **Simon Dew - VP EVOX Therapeutics Ltd.**	Using Human Genetics to Identify Drug Targets **Alun McCarthy - Vice President C4X Discovery Ltd.**
15:30 - 15:40	AFTERNOON COFFEE BREAK			AFTERNOON COFFEE BREAK		
15:40 - 16:00	1 - 1 MEETING *20min		1 - 1 MEETING *20min		1 - 1 MEETING *20min	
16:00 - 17:00	How much influence do Investors play in making a decision on where to Outsource? Cost vs Speed vs Quality?	The right technology at the right time to conduct ADME/Tox screening of a drug candidate saving time & money in the process of obtaining regulatory approval	Optimizing Chemical Reactions with Deep Reinforcement Learning	cryo-EM (a rapidly developing methodology quickly being deployed for difficult to crystallize proteins)	How to improve current alliances and gain more effective collaborations **Paul Peter Tak - President & CEO Kintai Therapeutics**	Target discovery through functional genomics **Alexander Sheer - CSO Erytech**
17:00 - 17:30	INVESTOR'S PANEL		INVESTOR'S PANEL		INVESTOR'S PANEL	
17:30 - 19:00	DRINKS & CANAPE RECEPTION		DRINKS & CANAPE RECEPTION		DRINKS & CANAPE RECEPTION	

PREVIOUS PAGE | GO TO MENU | NEXT PAGE

PROVENTA INTERNATIONAL

INVESTMENTS & VENTURE CAPITAL

Introducing The New **'Investment & Venture Capital'** Track - Proventa International's latest evolutionary step in developing our signature Strategy Meetings. Now not only providing essential operational strategy solutions but also aiding in equally important fundraising and investment seeking strategy.

09:00 - 10:00	Management team, IP assets and proposition value: Key aspects to include in your investment pitch
11:00 - 12:00	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR
14:30 - 15:30	High risk; High reward. How to get funding for novel therapeutics for orphan diseases
16:00 - 17:00	How to turn Disruptive technologies into successful businesses with the adequate investment.

SPONSORS

CO-HOST

CDD VAULT Complexity Simplified

VISIT WEBSITE

Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological study data and chemical structures, and to collaborate with partners through a straightforward web interface.

optibrium

VISIT WEBSITE

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium's StarDrop™ provides a suite of integrated software with a highly visual and user-friendly interface enabling a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research. The company's new Augmented Chemistry™ platform delivers a unique & quot;deep learning" method, that has been demonstrated to provide more accurate and confident results than conventional predictive models of assay bioactivity data.

PerkinElmer For the Better

VISIT WEBSITE

Perkin Elmer provides innovative detection, imaging, informatics and service capabilities, with the knowledge and expertise needed to help customers gain earlier and more accurate insights to improve lives and the world around us.

PRO-PARTNERS

dotmatics knowledge solutions

VISIT WEBSITE

esQLABS WE EMPOWER HEALTH CARE

VISIT WEBSITE

ONTOFORCE EVERYBODY A DATA SCIENTIST

VISIT WEBSITE

NovAliX

VISIT WEBSITE

Recipharm good for business

VISIT WEBSITE

EXHIBITORS

药明康德 WuXi AppTec

VISIT WEBSITE

MEDICINAL CHEMISTRY BIOLOGY

HOTEL & TRAVEL

Radisson BLU
STANSTED

VISIT WEBSITE

MAP & TRAVEL

E-MAIL FOR +INFO

emilia@proventainternational.com

GO TO MENU



PROVENTA
INTERNATIONAL